Results 81 to 90 of about 3,367,527 (366)
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products
Drugs, 2015 Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These natural products have been vital for the development of multiagent treatment regimens currently ...
Matthew R Trendowski
semanticscholar +1 more source
Molecular Oncology, EarlyView.Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
Genetic and Modifiable Risk Factors Contributing to Cisplatin-Induced Toxicities [PDF]
, 2019 Effective administration of traditional cytotoxic chemotherapy is often limited by off-target toxicities. This clinical dilemma is epitomized by cisplatin, a platinating agent that has potent antineoplastic activity due to its affinity for DNA and other ...
Dinh, Paul C. Jr. +4 more
core +1 more source
Oral Antineoplastic Agents: Assessing the Delay in Care
Chemotherapy Research and Practice, 2015 The study was undertaken to determine the length of time between when a prescription for an oral antineoplastic agent is written by the provider and when the medication is received by the patient and to identify risk factors that significantly increase ...
Brandi Anders +2 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon +13 more
wiley +1 more source
Handling of injectable antineoplastic agents. [PDF]
BMJ, 1980 Although the clinical toxicity of antineoplastic drugs has been well documented there is little or no information on the problems that may arise on the handling and mishandling of such agents. This paper attempts to highlight the importance of taking precautions to prevent adverse effects resulting from contact with cytotoxic drugs during handling and ...
R S Knowles, J E Virden
openaire +3 more sources
Identification of Pharmacological Modulators of HMGB1-Induced Inflammatory Response by Cell-Based Screening [PDF]
, 2013 High mobility group box 1 (HMGB1), a highly conserved, ubiquitous protein, is released into the circulation during sterile inflammation (e.g. arthritis, trauma) and circulatory shock.
A Lahat +40 more
core +4 more sources
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management
Molecular Oncology, EarlyView.DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez +5 more
wiley +1 more source